ProKidney Corp.
rilparencel
chronic kidney disease (CKD)
Countdown
358days
Phase 3 readout · ~ Jun 30, 2027 estimated
What's at stake
Phase 3 trial results for rilparencel in chronic kidney disease (CKD) are due ~ Jun 30, 2027. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 15h ago
“We expect to complete enrollment in PROACT 1 this year, positioning us to deliver pivotal eGFR slope topline results in the second quarter of 2027.”